The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

When your skin is red, itchy, and irritated, it could be a rash or it might be hives. We spoke with experts to learn how to ...

Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...

Adults with chronic spontaneous urticaria experienced greater mortality, probably due to increased risks for comorbidities, ...

Urticaria or hives is a skin condition causing itchy red welts from various triggers Read ahead know its symptoms and why it often worsen at night ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, administration of the oral, highly selective Bruton's tyrosine kinase ...

Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, reduced itch and hives in patients with chronic spontaneous urticaria and showed a favorable safety profile at week 12 in two trials.

Allakos on Wednesday said Concentra Biosciences, controlled by life sciences-focused investment firm Tang Capital, has agreed to pay 33 cents a share in cash for the Menlo Park, Calif., company, a 52% ...

Please provide your email address to receive an email when new articles are posted on . Patients remained symptomatic despite H1 antihistamine care and had not tried omalizumab. 30.6% of the ...

Remibrutinib results in significant improvement in composite measure of itching and hives after second-generation H1-antihistamine treatment.